氯苯(CB)与干扰素(α -2b)联合氯苯治疗低级别非霍奇金淋巴瘤的随机研究:一项随机研究的中期报告

Teodoro Chisesi , Marina Congiu , Antonio Contu , Paolo Coser , Luciano Moretti , Adolfo Porcellini , Laura Rancan VI , Luigi Salvagno , Gino Santini , Orazio Vinante , Non-Hodgkin's Lymphoma Cooperative Study Group
{"title":"氯苯(CB)与干扰素(α -2b)联合氯苯治疗低级别非霍奇金淋巴瘤的随机研究:一项随机研究的中期报告","authors":"Teodoro Chisesi ,&nbsp;Marina Congiu ,&nbsp;Antonio Contu ,&nbsp;Paolo Coser ,&nbsp;Luciano Moretti ,&nbsp;Adolfo Porcellini ,&nbsp;Laura Rancan VI ,&nbsp;Luigi Salvagno ,&nbsp;Gino Santini ,&nbsp;Orazio Vinante ,&nbsp;Non-Hodgkin's Lymphoma Cooperative Study Group","doi":"10.1016/0277-5379(91)90566-V","DOIUrl":null,"url":null,"abstract":"<div><p>Alpha interferon has shown initial promise in the treatment of low-grade non-Hodgkin's lymphoma (NHL), especially with the nodular form of the disease. The present study enrolled 70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m<sup>2</sup> subcutaneously three times a week). Among 63 evaluable patients, similar response rates (62.1% and 64.7% respectively) were recorded for the treatment arms. In patients receiving no maintenance therapy, those who received interferon alfa-2b during the induction phase showed a favourable trend in terms of incidence of relapse compared to those who had received chlorambucil alone. During maintenance therapy with interferon alfa-2b, no significant differences in the occurrence of relapse have yet been seen compared to patients on no maintenance therapy. A longer observation period is needed to make a definitive conclusion about the usefulness of interferon maintenance therapy and to evaluate further the effects of the combined schedule of chlorambucil and interferon induction on the duration of remission.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S31-S33"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90566-V","citationCount":"31","resultStr":"{\"title\":\"Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: An interim report of a randomized study\",\"authors\":\"Teodoro Chisesi ,&nbsp;Marina Congiu ,&nbsp;Antonio Contu ,&nbsp;Paolo Coser ,&nbsp;Luciano Moretti ,&nbsp;Adolfo Porcellini ,&nbsp;Laura Rancan VI ,&nbsp;Luigi Salvagno ,&nbsp;Gino Santini ,&nbsp;Orazio Vinante ,&nbsp;Non-Hodgkin's Lymphoma Cooperative Study Group\",\"doi\":\"10.1016/0277-5379(91)90566-V\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Alpha interferon has shown initial promise in the treatment of low-grade non-Hodgkin's lymphoma (NHL), especially with the nodular form of the disease. The present study enrolled 70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m<sup>2</sup> subcutaneously three times a week). Among 63 evaluable patients, similar response rates (62.1% and 64.7% respectively) were recorded for the treatment arms. In patients receiving no maintenance therapy, those who received interferon alfa-2b during the induction phase showed a favourable trend in terms of incidence of relapse compared to those who had received chlorambucil alone. During maintenance therapy with interferon alfa-2b, no significant differences in the occurrence of relapse have yet been seen compared to patients on no maintenance therapy. A longer observation period is needed to make a definitive conclusion about the usefulness of interferon maintenance therapy and to evaluate further the effects of the combined schedule of chlorambucil and interferon induction on the duration of remission.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":\"27 \",\"pages\":\"Pages S31-S33\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90566-V\",\"citationCount\":\"31\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/027753799190566V\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190566V","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 31

摘要

α干扰素在治疗低级别非霍奇金淋巴瘤(NHL),尤其是结节性淋巴瘤方面显示出初步的前景。本研究招募了70名NHL患者,他们接受了氯苯(CB);10 mg/天)或CB加干扰素α -2b(500万单位(MU)/m2,每周皮下注射3次)。在63名可评估的患者中,治疗组的有效率相似(分别为62.1%和64.7%)。在未接受维持治疗的患者中,在诱导期接受干扰素α -2b治疗的患者与单独接受氯霉素治疗的患者相比,在复发发生率方面显示出有利的趋势。在干扰素α -2b维持治疗期间,与未接受维持治疗的患者相比,复发发生率未见显着差异。需要更长的观察期才能对干扰素维持治疗的有效性做出明确的结论,并进一步评估氯霉素和干扰素诱导联合方案对缓解持续时间的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: An interim report of a randomized study

Alpha interferon has shown initial promise in the treatment of low-grade non-Hodgkin's lymphoma (NHL), especially with the nodular form of the disease. The present study enrolled 70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m2 subcutaneously three times a week). Among 63 evaluable patients, similar response rates (62.1% and 64.7% respectively) were recorded for the treatment arms. In patients receiving no maintenance therapy, those who received interferon alfa-2b during the induction phase showed a favourable trend in terms of incidence of relapse compared to those who had received chlorambucil alone. During maintenance therapy with interferon alfa-2b, no significant differences in the occurrence of relapse have yet been seen compared to patients on no maintenance therapy. A longer observation period is needed to make a definitive conclusion about the usefulness of interferon maintenance therapy and to evaluate further the effects of the combined schedule of chlorambucil and interferon induction on the duration of remission.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信